{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+Product+1", "query": { "intervention": "Experimental Product 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1344, "total_pages": 135, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Experimental+Product+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T00:19:09.053Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02341443", "title": "A Multicenter RCT to Investigate the Treatment of Double (Bilateral) Mandibular Fractures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mandibular Fractures" ], "interventions": [ { "name": "Implants", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "AO Clinical Investigation and Publishing Documentation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2015-04", "completion_date": "2019-05", "has_results": false, "last_update_posted_date": "2020-08-19", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 2, "location_summary": "New York, New York • San Antonio, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02341443" }, { "nct_id": "NCT01170286", "title": "Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peanut Allergy" ], "interventions": [ { "name": "Whole peanut extract", "type": "BIOLOGICAL" }, { "name": "Placebo formulation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "DBV Technologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "6 Years to 50 Years" }, "enrollment_count": 100, "start_date": "2010-07", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2012-03-23", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Denver", "state": "Colorado" }, { "city": "Willingboro", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Orem", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01170286" }, { "nct_id": "NCT02016924", "title": "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "BR", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "LPV/r", "type": "DRUG" }, { "name": "Third Unboosted Drug", "type": "DRUG" }, { "name": "Cobicistat TOS", "type": "DRUG" }, { "name": "F/TAF TOS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 133, "start_date": "2014-01-16", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 7, "location_summary": "Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02016924" }, { "nct_id": "NCT07361562", "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor, Adult", "ERBB2 Altered Breast Cancer", "ERBB2 Gene Amplification", "HER2 Overexpression", "Non-Small Cell Lung Cancer", "HER2" ], "interventions": [ { "name": "CGT4255", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-12-30", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07361562" }, { "nct_id": "NCT03888482", "title": "Clinical Comparison of DDT2 Contact Lens and a Daily Disposable Contact Lens - Study 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Refractive Error", "Myopia" ], "interventions": [ { "name": "Verofilcon A contact lenses", "type": "DEVICE" }, { "name": "Somofilcon A contact lenses", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2019-04-26", "completion_date": "2019-06-28", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 8, "location_summary": "Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Powell", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03888482" }, { "nct_id": "NCT04056117", "title": "A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Shigellosis" ], "interventions": [ { "name": "Shigella 4V", "type": "BIOLOGICAL" }, { "name": "MenACWY", "type": "BIOLOGICAL" }, { "name": "Rabies", "type": "BIOLOGICAL" }, { "name": "Diphtheria, Tetanus and Pertussis (DTaP)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "LimmaTech Biologics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Months", "maximum_age": "50 Years", "sex": "ALL", "summary": "8 Months to 50 Years" }, "enrollment_count": 597, "start_date": "2019-09-02", "completion_date": "2022-11-14", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 0, "location_summary": "Not listed", "locations": [], "official_url": "https://clinicaltrials.gov/study/NCT04056117" }, { "nct_id": "NCT06100913", "title": "Immunology of Ebola Vaccine", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ebola Virus Disease" ], "interventions": [ { "name": "Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)", "type": "BIOLOGICAL" }, { "name": "Deuterium Labeled Water", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-08-06", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 2, "location_summary": "Decatur, Georgia • St Louis, Missouri", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06100913" }, { "nct_id": "NCT00040391", "title": "A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Diarrhea" ], "interventions": [ { "name": "Investigational drug", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-12-01", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Anaheim, California • Concord, California + 24 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Gilroy", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00040391" }, { "nct_id": "NCT02284568", "title": "A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Laquinimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "25 Years to 55 Years" }, "enrollment_count": 374, "start_date": "2015-01-12", "completion_date": "2017-10-01", "has_results": true, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Northbrook", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02284568" }, { "nct_id": "NCT07111078", "title": "Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza Prevention", "Pandemic Influenza Prevention" ], "interventions": [ { "name": "VRC-FLUMOS0122-00-VP", "type": "BIOLOGICAL" }, { "name": "ALFQ", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 56, "start_date": "2025-08-27", "completion_date": "2027-08-18", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-09T00:19:09.053Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07111078" } ] }